131 related articles for article (PubMed ID: 25572790)
1. What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?
Pirker R
Future Oncol; 2015; 11(1):153-67. PubMed ID: 25572790
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib in the first-line treatment of non-small-cell lung cancer.
D'Arcangelo M; Cappuzzo F
Expert Rev Anticancer Ther; 2013 May; 13(5):523-33. PubMed ID: 23617344
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
4. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy for NSCLC--A Double-edged Sword?
Dempke WC
Anticancer Res; 2015 May; 35(5):2503-12. PubMed ID: 25964523
[TBL] [Abstract][Full Text] [Related]
6. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.
Kao HF; Lin CC; Yang JC
Future Oncol; 2013 Jul; 9(7):991-1003. PubMed ID: 23837762
[TBL] [Abstract][Full Text] [Related]
7. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
[TBL] [Abstract][Full Text] [Related]
9. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Soria JC; Mok TS; Cappuzzo F; Jänne PA
Cancer Treat Rev; 2012 Aug; 38(5):416-30. PubMed ID: 22119437
[TBL] [Abstract][Full Text] [Related]
10. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Bronte G; Rolfo C; Giovannetti E; Cicero G; Pauwels P; Passiglia F; Castiglia M; Rizzo S; Vullo FL; Fiorentino E; Van Meerbeeck J; Russo A
Crit Rev Oncol Hematol; 2014 Feb; 89(2):300-13. PubMed ID: 24041630
[TBL] [Abstract][Full Text] [Related]
11. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
Zhang WQ; Li T; Li H
Med Sci Monit; 2014 Dec; 20():2666-76. PubMed ID: 25503781
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.
Cadranel J; Ruppert AM; Beau-Faller M; Wislez M
Crit Rev Oncol Hematol; 2013 Dec; 88(3):477-93. PubMed ID: 23911281
[TBL] [Abstract][Full Text] [Related]
15. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
[TBL] [Abstract][Full Text] [Related]
16. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
17. First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Neal JW; Sequist LV
Clin Adv Hematol Oncol; 2010 Feb; 8(2):119-26. PubMed ID: 20386533
[TBL] [Abstract][Full Text] [Related]
18. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S; Zimmermann S; Adjei AA
Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]